Dr.Reddy's Laboratories Ltd RDY:NYSE

Last Price$35.05NYSE Closing Price as of 6:30PM ET 8/21/19

Today's Change-0.29(0.82%)
Bid (Size)N/A (N/A)
Ask (Size)$35.90 (1)
Day Low / High$34.93 - 35.39
Volume89.0 K
 

Read more news Recent News

Asian ADRs Move Higher in Wednesday Trading
10:28AM ET 8/21/2019 MT Newswires

American depositary receipts of Asian stocks were trading 0.23% higher at 1,412.09 on the BNY Mellon Asia 50 ADR Index on Wednesday. In North Asia, the...

Asian ADRs Move Higher in Tuesday Trading
10:36AM ET 8/20/2019 MT Newswires

American depositary receipts of Asian stocks were trading 0.066% higher at 1,412.58 on the BNY Mellon Asia 50 ADR Index on Tuesday. In North Asia, the...

Dr. Reddy's Launches Generic Vigabatrin Powder in US
5:08AM ET 8/20/2019 MT Newswires

India-based drug maker Dr. Reddy's Laboratories Ltd. (RDY) said Tuesday it has launched Vigabatrin powder for oral solution, a therapeutic equivalent of...

Dr. Reddy's Launches Cancer Drug Versavo in India
5:42AM ET 8/19/2019 MT Newswires

India-based pharmaceutical company Dr. Reddy's Laboratories Ltd (RDY) said Monday it has launched Versavo, a biosimilar of Roche's cancer drug Avastin, in...

Company Profile

Business DescriptionDr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India. View company web site for more details
AddressDoor No. 8-2-337
Hyderabad, Telangana 500034
Phone+91.40.49002900
Number of Employees21,966
Recent SEC Filing08/21/20196-K
Chief Executive & Operating OfficerErez Israeli
President, CFO & Global Head-ITSaumen Chakraborty
Secretary & Compliance OfficerSandeep Poddar
Executive Vice President & Head-Branded MarketsM. V. Ramana

Company Highlights

Price Open$35.17
Previous Close$35.34
52 Week Range$31.58 - 42.82
Market Capitalization$5.8 B
Shares Outstanding165.9 M
SectorHealth Technology
IndustryPharmaceuticals: Generic
Current Dividend / Yield$0.28 / 0.80%
Dividend Ex-Date07/12/2019
Dividend Pay-Date08/15/2019
Dividend Yield 5 Year AverageN/A
Next Earnings Announcement10/25/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings19.73
Earnings per Share$1.56
Beta vs. S&P 500N/A
Revenue$2.2 B
Net Profit Margin13.47%
Return on Equity14.99%

Analyst Ratings as of 08/15/2019

Buy
17
Overweight
5
Hold
9
Underweight
5
Sell
6
Consensus RecommendationConsensus Icon
Powered by Factset